Aims: GPR40/FFAR1 mediates palmitate-induced stimulation of insulin secretion but its involvement in lipotoxicity is controversial. Our previous observations suggest that FFAR1/ GPR40 agonists protect against lipotoxicity although the underlying mechanism remains elusive. The present study examines the role of ERK1/2 and GPR40/FFAR1 in palmitateinduced stimulation of insulin secretion and beta cell death. Methods: Insulin secretion of INS-1E cells was measured by radioimmunoassay. Protein phosphorylation was examined on Western blots. Apoptosis was assessed by TUNEL staining. Results: Palmitate and the GPR40/ FFAR1 agonist TUG-469 increased phosphorylation of ERK1/2 at low (2.8 mmol/L) and high (12 mmol/L) glucose but stimulated insulin secretion only at high glucose. The MEK1 inhibitor PD98059 significantly reduced phosphorylation of ERK1/2 but did not reverse the stimulation of secretion induced by glucose, palmitate or TUG-469. PD98059 rather augmented glucose-induced secretion. Prolonged exposure to palmitate stimulated apoptosis, an effect counteracted by TUG-469. PD98059 accentuated palmitate-induced apoptosis and reversed TUG-469-mediated inhibition of cell death. Conclusions: Activation of ERK1/2 by palmitate and GPR40/FFAR1 agonist correlates neither with stimulation of insulin secretion nor with induction of apoptosis. The results suggest a significant anti-apoptotic role of ERK1/2 under conditions of lipotoxicity.
Introduction
The importance of FFAR1/GPR40 in fatty acid-mediated stimulation of insulin secretion is widely accepted [1, 2] . The role in lipotoxicity, however, is controversially discussed. Our previous observations indicate a protective effect of FFAR1/GPR40 against lipotoxicity [3] . However, other studies suggested that inhibition of FFAR1/GPR40 counteracted fatty acid-induced beta cell death [4, 5] . Using recombinantly expressed receptors, it has been proposed that GPR40/FFAR1 activates the extracellular signal-regulated protein kinases 1 and 2, ERK1/2 [6] .
The role of MAPK signalling pathways is manifold [7] . Activation of ERK1/2 by growth factors, including IGF-1, stimulates early genes and promotes proliferation. ERK1/2 further exerts effects on cell survival and differentiation. In insulin secreting cells stimulation of ERK1/2 parallels insulin secretion induced by glucose, by substances which increase cAMP (GLP-1, GIP) and by phorbol esters which activate PKCs, suggesting an involvement of ERK1/2 [8, 9] . IGF-1, glucose and incretins have additive effects on ERK1/2 activation [10] . Stimulation of ERK1/2 by IGF-1 is mediated via ras, raf-1 and MEK1 and is independent of an increase in cytosolic Ca 2+ [11] . On the contrary, activation of ERK1/2 by glucose depends on the increase in cytosolic Ca 2+ and on cAMP-induced stimulation of PKA which directly phosphorylates raf-1 [10, 12] .
The function of ERK1/2 is not completely understood due to contradictory observations. The MEK1 inhibitor PD98059 did not affect glucose-induced insulin secretion in INS-1E cells [13] . In contrast, inhibition of glucose-dependent ERK1/2 phosphorylation upon chronic exposure to palmitate was linked to a concomitant reduction in glucose-induced insulin secretion in Min6 cells [14] .
Furthermore, numerous observations suggested an anti-apoptotic role of ERK1/2, both in Min6 and INS-1E cells [15] [16] [17] [18] [19] . In line, ERK1/2 was shown to counteract CHOP expression, an ER-stress marker which strongly correlates with beta cell death [11, 20, 21] . However, these findings were challenged in isolated human islets, where inhibition of ERK1/2 by PD98059 antagonized glucotoxicity [22] . Thus, the involvement of ERK1/2 in insulin secretion and beta cell apoptosis remains elusive.
This study aims to understand the role of ERK1/2 in the regulation of insulin secretion and induction of apoptosis during acute and chronic exposure of insulin secreting INS-1E cells to the saturated fatty acid palmitate and the GPR40/FFAR1 agonist TUG-469.
Materials and Methods

Materials
INS-1E cells were kindly provided by C.B. Wollheim and P. Maechler (University of Geneva, Geneva, Switzerland) and TUG-469 was a kind gift from T. Ulven (Southern University of Denmark, Odense, Denmark). Fetal calf serum (FCS) was purchased from Serva (Heidelberg, Germany); MEK1 inhibitor PD98059 and antibodies against PKB (#9272), P-Thr183/Tyr185-JNK (#9251), P-Ser73-cJun (#9164), ERK1/2 (#9102), P-Thr202/Tyr204-ERK1/2 (#9101) and tubulin (#2148) were from Cell Signalling Technology Europe (Leiden, The Netherlands). The antibody against GAPDH (V-18, #sc-20357) was from Santa Cruz Biotechnology, Inc. (Heidelberg, Germany), horseradish peroxidase-coupled anti-rabbit IgG was from GE Healthcare (Buckinghamshire, U.K.), TUNEL assay from Roche Diagnostics GmbH (Basel, Switzerland). All other chemicals were purchased from Sigma-Aldrich (Deisenhofen, Germany).
Methods
Cell culture. INS-1E cells were kept under standard culture condition in RPMI1640 medium containing 11 mmol/L glucose and supplemented with 10% FCS, 10 mmol/L HEPES, 2 mmol/L L-glutamine, 1 mmol/L Na-pyruvate and 10 μmol/L 2-mercaptoethanol. Cells were treated with the MEK1 inhibitor PD98059 (10 µmol/L) 1h prior to and during exposure to palmitate, TUG-469 or phorbol myristate acetate (PMA).
Insulin secretion. Insulin secretion was measured in static incubation by using modified Krebs-Ringer buffer (KRB), containing in mmol/L: 135 NaCl, 4. . A stock solution of palmitate in DMSO (100 mmol/L) was diluted in FCS (containing 5 % albumin) or coupled to BSA (5% in KRB) such that the concentration of palmitate was 6 mmol/L. These solutions were diluted as required for the respective experiments keeping the palmitate/albumin ratio constant. The agonist TUG-469 was used at low albumin (FCS) concentration (0.05 % (w/v)) since higher concentrations of albumin inhibit TUG-469 effects on secretion (unpublished observations). TUNEL assay. Cells were seeded onto glass cover slips and cultured in the presence of test substances as indicated. After fixation with 4% PFA for 1h cells were permeabilized with 0.1% Triton X-100 in PBS and fractionated DNA was detected using a commercial kit (Roche Diagnostics). Nuclei were stained with 1 µmol/L TO-PRO3 or 0.1 µg/mL DAPI in PBS.
Western blotting. After treatment with test substances as indicated, cells were lysed in a buffer containing 125 mmol/L NaCl, 1% (v/v) Triton X-100, 0.5% Na-deoxycholate, 0.1% SDS, 10 mmol/L EDTA, 25 mmol/L HEPES, pH 7.3, 10 mmol/L NaPP, 10 mmol/L NaF, 1 mmol/L Na-vanadate, 10 µg/mL pepstatin A, 10 µg/mL aprotinin and 0.1 mmol/L PMSF as described previously [23] . Proteins (30 µg) of a 10.000g supernatant were subjected to SDS-PAGE and blotted on nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany). Membranes were incubated overnight with primary antibodies (1:1000) followed by incubation with the secondary anti-rabbit IgG (1:2000) . Results were quantified using ImageJ software (NIH, USA).
Statistical analysis. Data are presented as means ± SEM. Significance was tested using Student's t-test or ANOVA followed by Dunnett's or Newmann-Keul's post-tests as appropriate. Results with p<0.05 were considered statistically significant.
Results
Activation of ERK1/2 is not critical for palmitate-and TUG-469-induced insulin secretion
In order to correlate stimulation of ERK1/2 to insulin secretion, the effects of palmitate on ERK1/2 phosphorylation and insulin secretion were assessed in the absence and presence of the MEK1 inhibitor PD98059, 10 µmol/L (Fig. 1A-C) . Palmitate stimulated phosphorylation of ERK1/2 at 2.8 mmol/L glucose without inducing secretion. High glucose, 12 mmol/L, increased ERK1/2 phosphorylation along with an increase in secretion. Palmitate further augmented the glucose effect on secretion and phosphorylation of ERK1/2 remained high. However, PD98059 did not inhibit glucose-and palmitate-stimulation of secretion despite a significant reduction of ERK1/2 phosphorylation. Interestingly, glucose-induced insulin secretion was significantly augmented by PD98059. Furthermore the effect of palmitate on ERK1/2 phosphorylation and insulin secretion was mimicked by the selective FFAR1/ GPR40 agonist TUG-469, 10 µmol/L ( Fig. 2A-C) . Again, the inhibition by PD98059 did not lower insulin secretion. Of note, this effect of PD98059 was specific as the inhibitor did not significantly affect phosphorylation of JNK and its substrate, c-Jun (Fig. 3A-D) .
These results demonstrate that stimulation of ERK1/2 does not correlate with stimulation of insulin secretion suggesting, therefore, that ERK1/2 does not play a major role in palmitate-mediated, GPR40/FFAR1-dependent stimulation of insulin secretion in INS-1E cells.
Activation of ERK1/2 is not sufficient to induce beta cell death
To test whether ERK1/2 is activated under lipotoxic conditions, INS-1E cells were exposed to 600 µmol/L palmitate dissolved in culture medium containing 12 mmol/L glucose and supplemented with 10% FCS (Fig. 4A,B) . In parallel cells were treated with the phorbol ester, PMA (100 nmol/L). Both, palmitate and PMA significantly increased phosphorylation of ERK1/2 (Fig. 4A,B) . The effects, however, were transient and ERK1/2 phosphorylation returned to basal levels after 24h exposure to PMA as well as palmitate. Palmitate but not (Fig. 5A-C) .
In agreement with our previous observation, TUG-469 (10 µmol/L) did not augment beta cell death, but significantly reduced palmitate (50 µmol/L) induced apoptosis (Fig. 5D) . The protective effect of TUG-469 was antagonized by PD98059 (10 µmol/L). In conclusion, palmitate mediated activation of ERK1/2 depends at least in part on GPR40/FFAR1 and is neither crucial for stimulation of insulin secretion nor for induction of apoptosis. In contrast, the results suggest an anti-apoptotic role of ERK1/2 under conditions of lipotoxicity.
Discussion
This study reveals that the specific activation of GPR40/FFAR1 by TUG-469 mimics the stimulation of ERK1/2 induced by palmitate, indicating that GPR40/FFAR1 activation contributes to this effect of palmitate. Intriguingly, the activation of ERK1/2 does not seem to be decisive for GPR40/FFAR1-dependent stimulation of insulin secretion, since the efficient inhibition of ERK1/2 by PD98059 did not affect stimulation of insulin secretion. The most prominent effect of PD98059 in our study was the accentuation of palmitateinduced beta cell death. As PD98059 also antagonized the protective effect of TUG-469 on apoptosis, we propose that the anti-apoptotic effect of GPR40/FFAR1 activation, which we described previously, involves the stimulation of ERK1/2 [3] . A comparable anti-apoptotic role for GPR40/FFAR1 has been suggested previously using the unsaturated fatty acid oleate which also activated ERK1/2 in NIT-1 cells [24] . In contrast to these observations another study associated ERK1/2 phosphorylation with insulin secretion and chronic stimulation of GPR40/FFAR1 with beta cell death [14] . An explanation for the differences could be the use of high concentrations of the MEK inhibitor U0126, which has been found to induce side effects such as increases in the cellular ratios of ADP/ATP and AMP/ATP [25] . This may explain the inhibitory effect of U0126 on secretion. Although high concentrations of PD98059 have similar unspecific effects, especially in the inhibition of other stress kinases, at the concentration used in our study, PD98059 inhibited ERK1/2 phosphorylation without affecting palmitate-induced phosphorylations of JNK and c-Jun (Fig. 3) . Interestingly, the muscarinic M3 receptor, which also couples via Gq to PLC, stimulates ERK1/2 and exerts protective effects in beta cells, supporting our findings [26] . Activation of ERK1/2, especially by glucose, has been linked to stimulation of insulin secretion [14] . In contrast, our study showed that a concentration of PD98059 (10 µmol/L), which was sufficient to reverse the effect of glucose on ERK1/2 phosphorylation, significantly augmented glucose-induced insulin secretion in INS-1E cells [13] . In Min6 cells glucose-induced insulin secretion was supported at least in part by ERK1/2-dependent phosphorylation of synapsin I [27] . However, in a recent study insulin secretion remained normal in synapsin I deficient beta cells doubting the role of synapsin I in insulin exocytosis [28] . Thus, the role of ERK1/2 in glucose-induced insulin secretion remains elusive.
Furthermore, palmitate-induced phosphorylation of ERK1/2 was not decisive for insulin secretion. PD98059 significantly reduced phosphorylation of ERK1/2 without affecting palmitate-dependent stimulation of insulin secretion. Moreover, basal secretion at 2.8 mmol/L glucose was not stimulated by palmitate, although palmitate induced a strong phosphorylation of ERK1/2 at low glucose.
Of note, the stimulation of ERK1/2 phosphorylation by glucose and palmitate was at least partly additive, hinting at the presence of two distinct pathways which activate ERK1/2. One pathway involves the activation of PKCs and this pathway is activated by PMA, a strong albeit unselective activator of PKCs, but also by palmitate and probably glucose [29] [30] [31] . The other pathway involves a stimulation of ERK1/2 through an increase of cytosolic Ca 2+ , which is the main signalling pathway of glucose [12, 22] .
Thus, our observations do not support the idea that ERK1/2 activity is crucial for acute stimulation of insulin secretion by glucose and palmitate. Our study, however, does not exclude that ERK1/2 may exert indirect effects on secretion. ERK1/2 is involved in glucosedependent regulation of insulin gene transcription and thus supports insulin production [11] . In accordance, in mouse islets and the rat insulinoma cell line INS-1, overexpression of ERK2 increased insulin gene transcription, while a kinase inactive ERK2 mutant inhibited glucosestimulated transcription, suggesting that ERK2 positively affects insulin production [32] . In contrast, another study using the mouse insulinoma cell line Min6 suggested that glucosemediated stimulation of the insulin promoter via PDX-1 requires PI3K but not ERK1/2 [33] . Nevertheless, a long term exposure of insulin secreting cells to ERK1/2 inhibitors results in a reduction of insulin content and thus exhaustion of secretion.
In conclusion, GPR40/FFAR1 agonists, besides their beneficial effects on insulin secretion, may exert positive effects on beta cell survival possibly via stimulation of ERK1/2.
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